Clinical trials: Mild Respiratory Distress
Mild to Moderate Acute Respiratory Distress Syndrome
Post-Market Study of Low-flow ECCO2R Using PrismaLung+
PrismaLung+ is intended to provide extracorporeal carbon dioxide removal (ECCO2R) as a standalone therapy or in combination with continuous renal replacement therapy (CRRT).
- Trial name
- NCT04617093
- Testing
- PrismaLung+
- Where
- 10 sites in France
- Volunteers
- 63 people
- Sponsor
- Vantive Health LLC
Acute Respiratory Failure
Physiological Effects of a New Interface on Lung Ventilation and Gas Distribution
Hypoxemic Acute Respiratory Failure (hARF) is a common reason of admission to Intensive Care. Different modalities can be used to administer oxygen, which is the first supportive treatment in these patients.
- Trial name
- NCT04619641
- Testing
- High Flow Nasal Cannula (HFNC), Continuous Positive Airway Pressure (CPAP)
- Volunteers
- 15 people
- Sponsor
- University Magna Graecia
Respiratory Distress Syndrome, Adult
Roflumilast as add-on Therapy in Early Cases of ARDS
Mild cases of ARDS will be included in a two-arm protocol, to receive 500 mcg of roflumilast daily up to 28 days (FDA approved dose for COPD) plus standard of care versus standard of care alone.
- Trial name
- NCT04744090
- Testing
- Roflumilast
- Where
- 2 sites in Egypt
- Volunteers
- 76 people
- Sponsor
- Cairo University
Mild Respiratory Distress
A Dose Escalation Study of NanO2 in Patients With Mild Respiratory Distress
EXTEND is a dose escalation study of NanO2™ in patients with mild respiratory distress who are at risk for mechanical ventilation. The study will establish dosing guidelines for a Phase 2 study.
- Trial name
- EXTEND-1b (NCT06658535)
- Testing
- dodecafluoropentane (0.025 mL/kg), dodecafluoropentane (0.032 mL/kg), dodecafluoropentane (0.050 mL/kg)
- Where
- 2 sites in Canada
- Volunteers
- 18 people
- Sponsor
- NuvOx LLC
Covid19, Corona Virus Infection
Expanded Access to Zofin for Patients With COVID-19
This expanded access protocol will provide access to the investigational product Zofin for patients in outpatient facilities infected with SARS-CoV-2 who have mild to moderate COVID-19, or who are judged by a healthcare provider…
- Conditions
- Covid19, Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome), Acute Respiratory Distress Syndrome
- Trial name
- NCT04657406
- Testing
- Zofin
- Sponsor
- ZEO ScientifiX, Inc.
ARDS (Acute Respiratory Distress Syndrome)
Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT31-1 for Treating ARDS
This Phase 1/2A, randomized, double-blind study will evaluate the safety, tolerability, and pharmacokinetics (PK) of HT31-1 (hCitH3-mAb) in healthy adult volunteers and in patients with mild-to-moderate acute respiratory distress…
- Trial name
- NCT07449572
- Testing
- HT31-1, Saline (0.9%, sterile, for infusion)
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- HTIC, Inc
Complication of Surgical Procedure, Acute Respiratory Failure, Adult
Prospective Evaluation of a RIsk Score for Postoperative Pulmonary COmPlications in Europe
Prospective Evaluation of a RIsk Score for postoperative pulmonary COmPlications in Europe (PERISCOPE) is a multi-centre, international observational study of a random-sample cohort of patients undergoing a nonobstetric…
- Conditions
- Complication of Surgical Procedure, Acute Respiratory Failure, Adult, Postoperative Respiratory Complications, Pulmonary Failure
- Trial name
- PERISCOPE (NCT01346709)
- Where
- 63 sites in Albania, Belgium and 19 more
- Volunteers
- 5,450 people
- Sponsor
- European Society of Anaesthesiology
COVID-19, COVID-19 Acute Respiratory Distress Syndrome
Study of Cysteamine-pantetheine Disulfide (TTI-0102) in Mild to Moderate COVID-19
This is multi-center, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacodynamics (PD) and efficacy of TTI-0102 for the treatment of patients with mild to moderate COVID-19.
- Trial name
- NCT05212662
- Testing
- TTI-0102
- Sponsor
- Thiogenesis Therapeutics, Inc.
Acute Respiratory Distress Syndrome
Low-Flow CO2 Removal for Mild to Moderate ARDS With PRISMALUNG
This pilot observational study will assess changes in pH /PaO2 /PaCO2, Respiratory Rate and device CO2 clearance in the first 24 hours of Extracorporeal CO2 removal (ECCO2R) following tidal volume (Vt), and plateau pressure…
- Trial name
- NCT02606240
- Testing
- CO2 removal with PRISMALUNG in ARDS
- Where
- 5 sites in France
- Volunteers
- 20 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Kangaroo-Mother Care, Preterm Infants
Early Kangaroo Care vs. Standard Neonatal Practices: Impact on Survival and Outcomes in Preterm Infants
This study aims to evaluate the efficacy of Early Kangaroo Mother Care (KMC) compared to standard neonatal nursing practices in improving survival rates and nursing outcomes among preterm infants weighing less than 2000 grams…
- Trial name
- NCT06707376
- Testing
- Early Kangaroo Mother Care
- Where
- Egypt
- Volunteers
- 240 people
- Sponsor
- Jouf University
Neonatal Respiratory Distress Syndrome
A Study To InvestigateThe Safety, Tolerability And Efficacy Of Nebulised Curosurf® In Preterm Neonates With Respiratory Distress Syndrome (RDS)
The present study will mainly aim at investigating the safety, tolerability and efficacy of different escalating single doses administration of nebulised Curosurf®, in preterm neonates with RDS (Respiratory Distress Syndrome)…
- Trial name
- NCT03235986
- Testing
- nCPAP (nasal Continuous Positive Airway Pressure) + Nebulised Curosurf® (Part I), nCPAP (nasal Continuous Positive Airway Pressure) + Nebulised Curosurf® (Part II), nCPAP (nasal Continuous Positive Airway Pressure) alone (Part I)
- Where
- Italy
- Volunteers
- 166 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Acute Respiratory Distress Syndrome
Safety and Tolerance of Umbilical Cord Mesenchymal Stem Cells in Patients With Acute Respiratory Distress Syndrome
The goal of this clinical trial is to evaluate the safety and tolerability of multiple doses of human umbilical cord mesenchymal stem cell injection in patients with Mild to Moderate Acute Respiratory Distress Syndrome (ARDS)…
- Trial name
- NCT05983627
- Testing
- Human Umbilical Cord Mesenchymal Stem Cells
- Volunteers
- 9 people
- Sponsor
- Asia Cell Therapeutics (Shanghai) Co., Ltd.
Covid19
Use of Hyperbaric Oxygen Therapy to Treat COVID-19 Patients With Respiratory Distress
Investigate whether hyperbaric oxygen therapy treatment can become a viable treatment option for COVID-19. If successful, providers will be able to provide future COVID-19 patients with mild-to-moderate respiratory distress…
- Trial name
- HBOT (NCT04800120)
- Testing
- Hyperbaric Oxygen Therapy
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Steward St. Elizabeth's Medical Center of Boston, Inc.
ARDS, Acute Respiratory Distress Syndrome
Effect of Prone Positioning on Mortality in Patients With Mild to Moderate Acute Respiratory Distress Syndrome.
Acute respiratory distress syndrome (ARDS) accounts for almost 10% of intensive care units (ICU) admissions. Three ARDS stages have been defined, based on the PaO2/FIO2 ratio measured with positive end-expiratory pressure (PEEP)…
- Conditions
- ARDS, Acute Respiratory Distress Syndrome, Intensive Care Unit, Mechanical Ventilation
- Trial name
- PROMILD (NCT05056090)
- Testing
- Patients will receive MV in PP
- Where
- France
- Volunteers
- 656 people
- Sponsor
- University Hospital, Grenoble
Mild Respiratory Distress
Respiratory Transition Without Continuous Positive Airway Pressure
The primary aim of this research project is to determine if term neonates (37:0 to 41:6 weeks' gestational age) with mild respiratory distress can safely transition without continuous positive airway pressure (CPAP).
- Trial name
- NCT07390812
- Testing
- Transition without Continuous Positive Airway Pressure (CPAP), CPAP
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Hackensack Meridian Health
COVID, Covid-19
A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19
The purpose of this study is to evaluate the safety and effectiveness of APL-9 in adults with mild to moderate ARDS (acute respiratory distress syndrome) caused by COVID-19 who are hospitalized and require supplemental oxygen…
- Conditions
- COVID, Covid-19, Coronavirus, Coronavirus Infection
- Trial name
- NCT04402060
- Testing
- APL-9, Vehicle Control
- Where
- 24 sites in United States, Brazil
- Volunteers
- 72 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Acute Respiratory Failure
Effects of a New Interface for NIV on Respiratory Drive
This pilot physiologic randomized cross-over study was designed to investigate if, in patients with hARF, a new device combining high-flow oxygen through nasal cannula (HFNC) and continuous positive airway pressure (CPAP) reduces…
- Trial name
- NCT04619667
- Testing
- High Flow Nasal Cannula (HFNC), Continuous Positive Airway Pressure (CPAP)
- Volunteers
- 22 people
- Sponsor
- University Magna Graecia
Newborn Respiratory Distress Syndrome
HHHFNC (Heated Humidified High-Flow Nasal Cannula) Versus NCPAP for Respiratory Distress Syndrome of Prematurity
Preterm infants ranging from 29+0 to 36+6 weeks+days are randomly assigned to one of the following treatments as non invasive respiratory support if they develop mild to moderate Respiratory Distress Syndrome within 72 hrs from…
- Trial name
- NCT02570217
- Testing
- HHHFNC, NCPAP
- Where
- Italy
- Volunteers
- 316 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
COVID19 ARDS
Mild Hypothermia for COVID-19 ARDS
Some patients with COVID have abnormally high carbon dioxide and low oxygen levels despite being on the ventilator. The hypothesis of the study is that the application of mild hypothermia to patients with COVID will decrease…
- Trial name
- NCT04570462
- Testing
- Hypothermia Via Cooling Machine- Arctic Sun 5000
- Where
- United States
- Sponsor
- Northwell Health
Coronavirus Infections, Pneumonia, Viral
Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19
The scientific community is in search for novel therapies that can help to face the ongoing epidemics of novel Coronavirus (SARS-Cov-2) originated in China in December 2019.
- Conditions
- Coronavirus Infections, Pneumonia, Viral, Acute Respiratory Distress Syndrome
- Trial name
- NoCovid (NCT04305457)
- Testing
- Nitric Oxide
- Where
- 2 sites in United States
- Volunteers
- 62 people
- Sponsor
- Massachusetts General Hospital